



Post-Doctoral Fellowship In Early Oncology Clinical Development

for PharmD and PhD Graduates

Sponsored by

AstraZeneca 

in conjunction with



UNIVERSITY of MARYLAND
SCHOOL OF PHARMACY





OVERVIEW and OBJECTIVES

The AstraZeneca-University of Maryland Clinical Development Fellowship is an exclusive **2-year program** geared toward **PharmD and PhD graduates** with a penchant for clinical research in the pharmaceutical and biotechnology industries. Established in 2009, the fellowship has paved the career path for numerous to enter clinical development.

Two fellowship position will be recruited for in the 2026-2028 cycle:

1. PharmD Fellow – located at the **Boston, MA** or **Gaithersburg, MD** office
2. PhD Fellow – located at the **Gaithersburg, MD** office

Fellows in the program will be involved in the early clinical development of oncology therapeutics. These pharmaceutical products may include biologics and small molecules, as well as exciting new modalities (including ADCs and Immunotherapies). The key learning objectives of the fellowship program are to understand:

- Scientific research process (including hypothesis generation and development)
- Clinical Development role and part of a Study Team
- Protocol development and study design
- Clinical development plans
- Understanding of oncology efficacy and safety assessments
- Data analysis, interpretation, and presentation
- Preparation and review of safety narratives
- Presentation to internal and external stakeholders
- Professional communication including verbal and written
- Preceptorship of 4th year PharmD students from University of Maryland



Pascal Soriot
Chief Executive Officer

OUR PURPOSE AND VALUES



We Follow the Science

- I am curious and push the boundaries of science
- I am creative in how I work with partners and collaborators



We Put Patients First

- I am proud to serve patients and consider them in every decision I take
- I strive to understand patients' needs and act accordingly



We Play To Win

- I am determined to make the right choices to win
- I build high performing teams that collaborate across the enterprise



We Do The Right Thing

- I am accountable for my actions and the success of AZ
- I speak up to ensure that all we do is aligned to our values



We Are Entrepreneurial

- I am brave, resilient and take smart risks
- I act with urgency and simplify the way work gets done

ABOUT ASTRAZENECA

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of life-changing medicines that contribute value to patients and society. AstraZeneca's innovative science and leadership are concentrated in three main therapy areas: oncology; respiratory; cardiovascular, renal, and metabolic disease (CVRM).

AstraZeneca North America research operations are headquartered in **Gaithersburg, Maryland** (25 miles from Washington, DC) one of AstraZeneca's Five global R&D centers, with additional sites in **Boston, MA; Cambridge, United Kingdom; Gothenburg, Sweden; Shanghai and Beijing, China**. With a drive to follow the science, AstraZeneca employs some of the best scientific minds in the industry who continually push the boundaries of science to deliver life-changing medicines.

AstraZeneca currently has 196 projects in development with 19 new molecular entities in late-stage trials, and 1 new molecular entities under review - one of the most robust pipelines in the industry. The Gaithersburg site includes ~5,000 employees in a state-of-the-art building that supports drug development from discovery to clinical development.



Post-Doctoral Fellowship
Early Oncology Clinical Development



Gaithersburg, Maryland



Cambridge, United Kingdom



Boston, Massachusetts

EARLY ONCOLOGY RESEARCH & DEVELOPMENT - EXECUTIVE LEADERSHIP



Susan Galbraith
MB., BChir., Ph.D
Executive Vice President
Oncology R&D



Matt Hellmann, MD
Vice President
Head of Clinical Group
Early Oncology

EARLY ONCOLOGY CLINICAL SCIENCE – LEADERSHIP TEAM



Matthew Farmer,
BSc PhD

Executive Director
Head of Oncology
Clinical Science
Early Oncology Clinical
Cambridge, UK



Oday Hamid,
PharmD

Sr. Group Director
Early Oncology
Clinical Science
Gaithersburg, MD



Maureen Hattersley

Sr. Group Director
Early Oncology
Clinical Science
Boston, MA



Shethah Morgan,
PhD

Sr. Group Director
Early Oncology
Clinical Science
Cambridge, UK



Simon Watkins,
PhD

Sr. Group Director
Early Oncology
Clinical Science
Cambridge, UK

FELLOWSHIP STEERING COMMITTEE



**Matthew Farmer,
BSc PhD**

Executive Director
Head of Oncology
Clinical Science
Early Clinical Oncology



**Oday Hamid,
PharmD**

Fellowship Program Director
Sr. Group Director
Early Oncology
Clinical Science



**Alkis Papachristos,
PharmD, PhD**

Clinical Scientist Director
Early Oncology
Clinical Science



**Neel Shah,
PhD**

Clinical Scientist Director
Early Oncology
Clinical Science



**Benjamin Ridgway,
PharmD, MS**

Associate Director
Early Oncology
Clinical Science

CURRENT FELLOWS

1st Year



Felopater Faheem

PharmD
Early Oncology Clinical Science
University of North Carolina
School of Pharmacy

2nd Year



Nick Caprio

PharmD
Early Oncology Clinical Science
University of Maryland
School of Pharmacy



Joanna Shaju

PharmD, MS
Early Oncology Clinical Science
University of Maryland
School of Pharmacy



Oday Hamid, PharmD

Fellowship Director
Senior Director
Early Oncology Clinical Science
AstraZeneca

The University of Maryland –AstraZeneca fellowship program provides intensive, specialized training to understand the drug development process and study management experience with emphasis on the development of the post-doctoral individual to succeed in the pharmaceutical industry. The intent is to prepare the fellow with an exceptional learning and mentorship experience as they enter their longer-term career in drug development.



Audra Stinchcomb, RPh, PhD

Fellowship Program Director
Professor of Pharmaceutical Sciences
University of Maryland School of Pharmacy

The University of Maryland School of Pharmacy's partnership with AstraZeneca makes available a unique clinical development fellowship to new graduates who are interested in pursuing careers in the pharmaceutical and biotechnology industries. This fellowship not only provides a wonderful training opportunity for outstanding graduates but also creates a pipeline for the development of highly qualified scientists who will be at the forefront of creating new medicines for the treatment of a variety of diseases. This innovative educational and research opportunity allows fellows to experience firsthand the work environment and challenges of the pharmaceutical industry. Furthermore, the fellowship allows students to leverage their PharmD education and apply it to real-world applications. As evidenced by the success of former fellows, AstraZeneca Clinical Development Fellows are uniquely positioned to compete in the highly competitive pharmaceutical and biotechnology industry. Thus, this opportunity provides an exciting springboard for a highly successful career at AstraZeneca and beyond.

STATEMENTS FROM FORMER FELLOWS



Benjamin Ridgway
PharmD, MS

Associate Director
Early Oncology Clinical Science
AstraZeneca
Former Fellow

The AstraZeneca-University of Maryland post-doctoral fellowship provides recent graduates with an avenue to learn the fundamentals of drug development, answering some of the most relevant and engaging clinical questions while working alongside experienced professionals who are invested in student success. This means the chance to join a team of industry veterans tackling the unique challenges that arise from running innovative trials of novel drugs, from monitoring for safety signals to establishing a dose to take to later stage trials, all with the aim of improving the lives of patients.



Alula Yohannes
PharmD, MS

Associate Director
Early Oncology Clinical Science
AstraZeneca
Former Fellow

The fellowship afforded me the opportunity to learn about the drug development process and was structured to optimize my exposure to different stages of clinical development. I was constantly learning and applying new concepts and engaging in real time clinical study management while working with a team of experienced and dedicated clinical professionals who fostered an environment of collaboration and cooperation that accelerated my learning process and made AstraZeneca a great place to work. The program was challenging yet rewarding while preparing me for my professional career journey in oncology clinical development.



Stephanie Udoe, PharmD

Medical Scientist, Late Oncology
AstraZeneca
Former Fellow

This fellowship is a unique opportunity to immerse oneself in the dynamic role a clinical scientist plays in the drug development process. It arms fellows with the skills needed to act as contributing members to the clinical development team, working towards curating novel therapies and combination treatments for populations with high unmet needs. A spirit of innovation and collaboration thrives at AstraZeneca, fostering an open environment for ample learning and creativity. The fellowship opens the door to training opportunities that adequately prepare its fellows for a career in industry.



Elie Pommier, PharmD

Associate Director
Clinical Development Oncology
AstraZeneca
Former Fellow

Through the clinical drug development post-doctoral program at AstraZeneca, I was able to learn invaluable skills such as understanding clinical trial design, protocol development, the scientific research process, and much more. Through this opportunity, I was also able to apply the clinical science I had learned in school to help assess patient profiles for safety as well as the efficacy of the investigational drugs we work on here at AstraZeneca.

[CLICK TO HOME PAGE](#)



**Post-Doctoral Fellowship
Early Oncology Clinical Development**